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INTRODUCTION
The syndrome of resistance to thyroid hormone (RTH; MIM 188570) is characterized by elevated serum free thyroid hormones (TH) in the presence of unsuppressed TSH levels, reflecting resistance to the normal negative feedback mechanisms in the hypothalamus and pituitary. 1 The degree of resistance within peripheral tissues determines whether thyrotoxic clinical features are associated with this condition. 1 
RTH is caused by a mutation in the TH receptor (TR)-ß gene (THRB; MIM 190160).
To date, more than 300 families with the RTH phenotype have been found to harbor mutations in this gene. 2 The mutant TR interferes with the activity of normal TR to induce the clinical syndrome. 3 Identification of an autosomal dominant mode of inheritance, in conjunction with the recognition that receptor mutants are functionally impaired, has led to the proposal that these abnormal proteins are able to inhibit the function of their wildtype counterparts in a dominant negative manner. 1 However, sporadic de novo cases are also common, although recessive inheritance is rare. 4 The phenotype of RTH is variable, with most patients presenting with mild to moderate symptoms. 5 Since its first description by Refetoff et al in 1967, 6 classic features have been progressively identified, including attention deficit and hyperactivity disorder, growth delay, tachycardia, and goiter. However, other features, such as frequent ear, nose and throat infections, hearing deficit, and decreased bone mass, have recently been recognized. 5 As RTH patients present with elevated TH levels and goiter, frequently accompanied by some manifestations of thyrotoxicosis, the condition is often misdiagnosed as Graves' disease. However, exophthalmos has never been identified as a feature of RTH and thyroid auto-antibodies have been detected only in approximately 4% of patients. 7 In these patients, an impairment of the glucose metabolism has not, to our knowledge, been reported. In this case report, we describe a girl with THR and diabetes mellitus, while we also discuss the potential mechanisms of this association.
CLINICAL REPORT
The patient, a female aged 10 years and 7 months, was referred to our Paediatric Endocrinology Unit for low body mass index (BMI) and suspected diagnosis of hyperthyroidism.
The proposita was the third-born child of a nonconsanguineous marriage delivered normally at 40 weeks after an uncomplicated pregnancy. Family history was suggestive of thyroid pathologies and type 2 diabetes mellitus (T2DM); the mother showed a history positive for goiter, hyperthyroidism, and fasting hyperglycaemia, diagnosed until adolescence. Three aunts have a history of thyroid diseases with goiter and unspecified dysthyroidism. One of these also showed impaired glucose tolerance (IGT), starting from the age of 34 years. One brother died of sudden infant death syndrome at three months of age. The other brother, 18 yrs old, was without any medical problems.
At birth, the girl's Apgar score was 10 I -10 V . Birth weight was 2.6 Kg (-1.90 SDS), length was 48 cm (-1.40 SDS) and head circumference 33.5 cm (-1.03 SDS). The neonatal congenital hypothyroidism screening was negative.
At 10 years and 7 months of age the girl weighed 26.6 kg (-1.75 SDS) and her height was 144 cm (-0.20 SDS). BMI was 12.80 (-3.00 SDS), according Cacciari et al. 8 The girl had no dysmorphic features. Her pubertal staging was B2-PH1-AH1. Her history was positive for frequent headache episodes and learning difficulty in school. At physical examination she appeared as hyperactive. There was no exophthalmos, muscle weakness or tremor. There was no erythema or onycholysis. The neurological and audiometric examinations were normal. Her blood pressure was 110/70 mmHg and her pulse rate was 110 beats/min. The skeletal muscles appeared hypotrophic and the adipose tissue reduced. The patient's thyroid gland was slightly and symmetrically enlarged.
Basal hormonal investigation revealed fT4 4.26 ng/dL (normal range: 0.8-1.9), fT3 8.02 pg/mL (normal range: 1.6-4.8), TSH 3.90 μIU/mL (normal range: 0.4-4). Antibodies against thyroperoxidase, thyroglobulin, and TSHR were undetectable. The fundus oculi, ECG, and echocardiography were normal.
Ultrasound examination of the neck showed an in-place, slightly enlarged thyroid gland. Bone age, performed according to the Greulich and Pyle method, was correspondent to chronological age (10 years vs. 10 years 7 months).
Other laboratory examinations showed normal haemoglobin levels (135 g/L; normal range: 120-150 g/L), mean corpuscular volume (MCV) (75.7 fL; normal range: 75-90 fL), serum cortisol (18 mg/dL; 08 AM normal range 5-25 mg/dL), adrenocorticotropic hormone (ACTH) (08 AM 35 pg/mL; normal range 9-52 pg/mL), 30's prolactin (PRL) (100 mIU/L; normal range 63-426 mIU/L), total calcium (2.3 mmol/L; normal range 2.2-2.7 mmol/L), phosphate However, an oral glucose tolerance test indicated diabetes mellitus with hyperinsulinism and insulin resistance: glycaemia was 131 mg/dL at 0', and 205 mg/dL at 120', whereas insulin was 34.6 μU/mL at 0', and 78.8 μU/mL at 120' (Table 1) . Homeostasis Model Assessment -Insulin Resistance (HOMA-IR) index (11.19) and Matsuda index (1.29) indicated insulin resistance.
Coeliac disease screening was negative (IgA 129 mg/dL; anti-tissue transglutaminase (tTG) antibodies 0.5 U/mL). The HLA was DQ2 DR3, 11 DRB3* DRw52.
Routine cytogenetic investigations revealed an apparently normal female karyotype (46,XX). For the next diagnostic plan, the sequence analysis of the TR gene revealed a mutation in exon 9 and an amino acid alteration, namely, a substitution of valine for methonine at codon 313 (Met313Val) ( Figure  1 ). This mutation has not, to our knowledge, been described in the literature. The same mutation was detected in the mother and in two maternal aunts (one with IGT).
Therefore, the proposita was started on a 3,5,5'-triiodothyroacetic acid (Triac) therapy at the initial dose of 1 mg/d. At the same time, nutritional recommendations and interventions were also initiated for diabetes.
Almost one year after long-term Triac therapy (11 years 9 months of age), the girl weighed 30.2 kg (-1.83 SDS) and her height was 149.6 cm (-0.11 SDS). BMI was 13.49 (-2.78 SDS), according Cacciari et al. 8 The girl had no dysmorphic features. The pubertal staging was B2-3-PH2-AH1.
We noted a reduction of thyroid hormone levels: fT4 2.47 ng/dL, fT3 5.23 pg/mL, TSH 2.60. We also observed an amelioration of glucose and insulin metabolism: HbA1c was 5.2%, basal glycaemia was 104 mg/dl, and basal insulin was 18.3 μU/mL. However, triglycerides were 108 mg/dL, total cholesterol 176 mg/dL, HDL cholesterol 53 mg/dL, LDL cholesterol 101 mg/dL. After a new oral glucose tolerance test, we hypothesized that glucose metabolism could be ameliorated by Triac treatment, possibly by improving insulin sensitivity (Table 1 ). In fact, basal glycaemia was 106 mg/dL (116 mg/dL at 120') and basal insulin 15.4 μU/mL (31.2 μU/mL at 120'). HOMA index was 4.03 and Matsuda index 3.50.
DISCUSSION
Resistance to thyroid hormone is an uncommon disorder characterized by elevated circulating THs with nonsuppressed TSH levels, reflecting resistance within the hypothalamic-pituitary-thyroid axis but variable refractoriness to hormone action in peripheral tissues. 9 Clinically, RTH can be divided into two entities: generalized (GRTH) and pituitary (PRTH) resistance. 3 A molecular mechanism to explain these two clinical phenotypes has proven elusive and many authors have concluded that they are part of a spectrum of the same disorder. 10 However, most subjects with GRTH are either asymptomatic or have nonspecific symptoms and are deemed to be in a compensated euthyroid state. In contrast, a subset of affected individuals can exhibit some clinical features of hyperthyroidism, suggesting greater central or pituitary RTH than in peripheral tissues.
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A possible, partial, explanation may be tissuedependent TRs expression. In fact, although TR 1 and TR 1 are expressed ubiquitously, TR 1 is expressed predominantly in the heart, bone, brain, and skeletal muscle, 11 whereas TR 1 is expressed more abundantly in liver, kidney, and thyroid. 10 However, TR 2 expression is limited to the pituitary gland, hypothalamus, retina, and inner ear. 10 In the murin pancreas, TR 1 is mainly expressed in -cells. 12 On the other hand, T3 rapidly induces Akt activation, with specific non-genomic action, in pancreatic -cells via TR 1. Thus, T3 could be considered a survival factor protecting islet -cells from apoptosis. 13 Besides this, the predominance of an receptor isoform in skeletal muscle may explain retention of sensitivity to TH by this target tissue, though some observations also support the notion that skeletal muscle is less refractory to TH action than the hypothalamic-pituitary axis in RTH. 11 Patients with RTH usually present with goiter and a euthyroid or mildly hypothyroid metabolic state. 14 However, the clinical presentation of the disease may be hypothyroidism, with symptoms such as delayed growth, cognitive dysfunction, and hypercholesterolaemia and, concurrently, signs consistent with hyperthyroidism, including tachycardia, weight loss, attention deficit-hyperactivity disorder, and advanced bone age. 15 The hypothyroid-like effects are presumably the consequence of mutant TR interference with, or inhibition of, normal T3 signalling pathways, whereas the signs reflective of hyperthyroidism result from the elevated T3 driving the activity of the TR 1 isoform. 15 The secondary occurrence of T2DM with pituitary, adrenal, and/or thyroid diseases is a recurrent observation. 16 Indeed, IGT and overt diabetes mellitus have frequently been associated with acromegaly, hypercortisolism, and hyperthyroidism. 16 Several studies evaluating the genomic and nongenomic effects of TH on insulin secretion have been conducted in order to clarify the mechanism(s) behind the IGT observed in hyperthyroidism. 17 For example, in rats treated with high and low doses of T4, fasting blood glucose levels were increased, but serum insulin levels were similar to those of controls. 17 By contrast, in rats treated only with high doses of T4, after an oral glucose load, blood glucose levels were increased, but serum insulin levels were decreased. 17 Hence, in animals, a deficient pancreatic -cell response to glucose, rather than insulin resistance, seems to be responsible for the abnormal glucose tolerance. 17 Notwithstanding, in humans, a recent study of Mitchell et al showed that RTH subjects exhibited insulin resistance as reflected by HOMA-IR. 11 In fact, in a subgroup of five RTH patients undergoing an OGTT, the ISI tended to be significantly lower and HOMA significantly higher than controls, clearly indicating the presence of an insulin-resistance. 11 One possible explanation for these discrepant results between animal models and humans may be that besides stimulating muscle fat oxidation and mitochondrial energy uncoupling in skeletal muscle, TH also promotes myocellular lipogenesis. A further possibility is that the liver RTH action might influence hepatic insulin sensitivity.
A key phenotype associated with T2DM in humans is impaired mitochondrial oxidative metabolism in skeletal muscle, a pattern potentially contributing to increased lipid accumulation and impaired metabolic flexibility, in turn, central features of both insulin resistance and diabetes. 18 In fact, the insulin-resistant state with hyperglycaemia may also be due to TH effects on mitochondrial content and activity, which is important for steroidogenesis as well as insulin secretion and action. 19, 20 However, in thyrotoxicosis, insulin levels are determined by two key factors: increased release of biologically inactive insulin precursors and increased insulin breakdown. -cell response to a meal in patients with Graves' disease is characterized by a high proinsulin output in the hyperglycaemic state. 21 The ratio of C-peptide to proinsulin is decreased, suggesting a defect in the cleaving process. 22 The increase in cardiac output in hyperthyroidism leads to increased glomerular filtration rate and therefore increased insulin clearance. The combination of increased proinsulin secretion and increased insulin clearance results in a reduced steady state of circulating insulin in hyperthyroidism (Figure 2 ).
In addition to these secretion and clearance alterations, overweight hyperthyroid women lose their first-phase response to hyperglycaemia, demonstrating lower insulin peaks after intravenous glucose challenge, similar to what is observed in patients with early T2DM. 23 Finally, an interesting aspect of our case report may be the possible effect, certainly also associated with changes related to the lifestyle of our patient, of Triac treatment on glucose metabolism. Although there is to date no scientific elucidation of the action of Triac on the insulinaemic metabolism, it is known that Triac has a higher affinity for TR 1. 24 However, Triac inhibits leptin secretion and expression in white and brown adipocytes, whereas insulin has the opposite effect. 25 In particular, leptin exerts antidiabetic actions that are independent of its regulation of body weight and food intake, 26 correcting diabetes in animal models of type 1 and type 2 diabetes. In addition, long-term leptin replacement therapy seems to improve glycaemic control as well as insulin sensitivity in patients with severe insulin resistance due to lipodystrophy. 26 In conclusion, our data seem to show that some patients with RTH may develop an impaired glucose metabolism. We therefore suggest that glucose metabolism should be investigated in all patients with RTH. Fig re 2 . The effects of excess thyroid hormone on various organ systems resulting in altered glucose metabolism, potentially leading to diabetic ketoacidosis and thyroid storm. Thyroid hormone increases hepatic glucose output, decreases peripheral glucose disposal, increases inactive insulin secretion by the pancreas, and increases insulin clearance by the kidney. TSH indicates thyrotropin.
